Cargando…

HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China

HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n ...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xin, Hepkema, Bouke, Nolte, Ilja, Kushekhar, Kushi, Jongsma, Theo, Veenstra, Rianne, Poppema, Sibrand, Gao, Zifen, Visser, Lydia, Diepstra, Arjan, van den Berg, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280205/
https://www.ncbi.nlm.nih.gov/pubmed/22355400
http://dx.doi.org/10.1371/journal.pone.0031865
_version_ 1782223790561820672
author Huang, Xin
Hepkema, Bouke
Nolte, Ilja
Kushekhar, Kushi
Jongsma, Theo
Veenstra, Rianne
Poppema, Sibrand
Gao, Zifen
Visser, Lydia
Diepstra, Arjan
van den Berg, Anke
author_facet Huang, Xin
Hepkema, Bouke
Nolte, Ilja
Kushekhar, Kushi
Jongsma, Theo
Veenstra, Rianne
Poppema, Sibrand
Gao, Zifen
Visser, Lydia
Diepstra, Arjan
van den Berg, Anke
author_sort Huang, Xin
collection PubMed
description HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and controls (65% vs 66%) and between EBV+ and EBV− cHL patients (70% vs 61%). The frequency distribution of HLA-A2 subtypes was significantly different between EBV stratified cHL subgroups and controls. This difference was most striking for the HLA-A*02:07 type with a frequency of 38% in EBV+ cHL, 8% in EBV− cHL and 20% in controls. Significant differences were also observed for the HLA-A*02:07, HLA-A2 (non-02:07) and the A2-negative typings between EBV+ cHL vs controls (p = 0.028), EBV− cHL vs controls (p = 0.045) and EBV+ vs EBV− cHL cases (p = 2×10(−5)). In conclusion, HLA-A*02:07 is a predisposing allele for EBV+ cHL and a protective allele for EBV− cHL in the northern Chinese population.
format Online
Article
Text
id pubmed-3280205
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32802052012-02-21 HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China Huang, Xin Hepkema, Bouke Nolte, Ilja Kushekhar, Kushi Jongsma, Theo Veenstra, Rianne Poppema, Sibrand Gao, Zifen Visser, Lydia Diepstra, Arjan van den Berg, Anke PLoS One Research Article HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and controls (65% vs 66%) and between EBV+ and EBV− cHL patients (70% vs 61%). The frequency distribution of HLA-A2 subtypes was significantly different between EBV stratified cHL subgroups and controls. This difference was most striking for the HLA-A*02:07 type with a frequency of 38% in EBV+ cHL, 8% in EBV− cHL and 20% in controls. Significant differences were also observed for the HLA-A*02:07, HLA-A2 (non-02:07) and the A2-negative typings between EBV+ cHL vs controls (p = 0.028), EBV− cHL vs controls (p = 0.045) and EBV+ vs EBV− cHL cases (p = 2×10(−5)). In conclusion, HLA-A*02:07 is a predisposing allele for EBV+ cHL and a protective allele for EBV− cHL in the northern Chinese population. Public Library of Science 2012-02-15 /pmc/articles/PMC3280205/ /pubmed/22355400 http://dx.doi.org/10.1371/journal.pone.0031865 Text en Huang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Huang, Xin
Hepkema, Bouke
Nolte, Ilja
Kushekhar, Kushi
Jongsma, Theo
Veenstra, Rianne
Poppema, Sibrand
Gao, Zifen
Visser, Lydia
Diepstra, Arjan
van den Berg, Anke
HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title_full HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title_fullStr HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title_full_unstemmed HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title_short HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
title_sort hla-a*02:07 is a protective allele for ebv negative and a susceptibility allele for ebv positive classical hodgkin lymphoma in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280205/
https://www.ncbi.nlm.nih.gov/pubmed/22355400
http://dx.doi.org/10.1371/journal.pone.0031865
work_keys_str_mv AT huangxin hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT hepkemabouke hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT nolteilja hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT kushekharkushi hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT jongsmatheo hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT veenstrarianne hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT poppemasibrand hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT gaozifen hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT visserlydia hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT diepstraarjan hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina
AT vandenberganke hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina